First gene therapy injection targets rare brain disorder
NCT ID NCT07173153
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tests a one-time gene therapy injection into the spinal fluid for people with SLC6A1 neurodevelopmental disorder, a rare genetic condition. The study involves just 1 participant and will monitor safety and changes in behavior and development over 3 years. The goal is to see if replacing the faulty gene can improve symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- AAV9.SLC6A1 gene therapy
- What this could lead to
- If successful, this could point toward a treatment that improves symptoms of SLC6A1 neurodevelopmental disorder.
- What could go wrong
- This is a very early, small trial with only 1 participant, so results may not apply to others. Gene therapy also carries risks like immune reactions or toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 1 person
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Aug 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Confirmation of pathogenic mutation S295L in the SLC6A1 gene * Ability to cooperate and complete assessments per determination of the physician and therapists Exclusion Criteria: * Serological evidence of HIV infection, or Hepatitis B or C infection * Diagnosis of (or ongoing treatment) for an autoimmune disease * Presence of a medical condition or extenuating circumstance that, in the opinion of the Sponsor-Investigator, might compromise the participant's ability to comply with the protocol required testing or procedures or compromise the participant's wellbeing, safety, or clinical interpretability * Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥20.0 K/µL) or an absolute neutrophil count \< 1.5K/µL * Concomitant illness or requirement for chronic drug treatment that in the opinion of the Sponsor-Investigator creates unnecessary risks for gene transfer * AAV9 binding antibody titers \> 1:400 as determined by ELISA immunoassay * Contraindications for intrathecal injection procedure (e.g. spina bifida, meningitis, or clotting abnormalities) * Abnormal laboratory values in the clinically significant range upon normal values in the Nationwide Children's Hospital Laboratory. (GGT \> 78 U/L, Bilirubin ≥ 3.0 mg/dL , Creatinine ≥ 1.8 mg/dL, Hgb \< 8 or \> 18 g/dL; WBC \> 15,000 cells per mL) * Family does not want to disclose participant's study participation with primary care physician and other medical providers. * Bleeding disorder or any other medical conditions or circumstances in which intrathecal (IT) administration of the product or lumbar puncture (for collection of CSF) are contradicted according to local institutional policy * Two consecutive aminotransaminase liver tests \>3 times the upper limit of normal) at screening * Contraindications for MRI scans (e.g., cardiac pacemaker, metal fragment or chip in the eye, aneurysm clip in the brain
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLC6A1 are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Nationwide Children's Hospital
Columbus, Ohio, 43205, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.